Brought to you by 
Serum Institute gets license to Visterra's dengue candidate in the Indian subcontinent
25 Sep 2017
Executive Summary
Visterra Inc. licensed Serum Institute of India Ltd. exclusive rights to develop, manufacture, and commercialize VIS513 for dengue virus in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives, and Sri Lanka.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Serum Institute gets license to Visterra's dengue candidate in the Indian subcontinent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice